Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug
** Shares of Amplia Therapeutics ATX.AX rise as much as
36.7% to A$0.135, set for best day since Aug 6, if gains hold
** The drug developer says the United States Food and Drug
Administration (FDA) has granted fast-track designation to co's
drug narmafotinib
** Drug used to treat advanced pancreatic cancer
** Stock hits highest since Sept 2
** Amplia stock up 67.2% YTD, as of 1255 GMT
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com;))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement